Average weight loss on Mounjaro: what the trial data actually shows

Step 1: understanding what the 72-week trial average represents

The 20–21% figure is not a best-case scenario pulled from a small subgroup. It is the mean weight reduction at 72 weeks among adults on the 15mg maintenance dose in SURMOUNT-1, a placebo-controlled trial of 2,539 participants. At 10mg, the average was around 19%; at 5mg, around 15%. Placebo participants, who received lifestyle support throughout, lost roughly 3%.

A few things worth knowing about how that average is constructed. Some participants lost considerably more; some lost less. Trial participants followed structured diet and activity counselling alongside the medicine, something the NICE appraisal of tirzepatide (TA1026) noted as important context when interpreting figures for routine clinical use. The trial was also conducted over a fixed period: weight loss tends to slow and plateau as the body adapts, so the 72-week mark captures a meaningful arc but not a final endpoint for everyone.

If you are wondering what the average looks like broken down week by week, there is more detail on how Mounjaro weight loss tends to progress each week. The short answer: early weeks often show faster change as appetite drops, with the rate gradually settling.

Step 2: how dose titration shapes the journey, and the result

Mounjaro is not taken at its maintenance dose from day one. Treatment starts at 2.5mg for the first four weeks, a dose whose job is to help your system adjust, not to drive significant weight loss. From there, the prescriber titrates upward, typically in four-week steps through 5mg, 7.5mg, 10mg, 12.5mg and 15mg, depending on how the patient tolerates each level.

This matters for setting expectations. Someone measuring their weight loss in the first month on Mounjaro is still on the starter dose and should not benchmark against the 15mg trial average. The bigger numbers in the data reflect many months of treatment at maintenance doses. Honestly, that is something a lot of people feel impatient about, the early weeks can feel slow, which is normal and, in fact, a sign the titration is working as intended.

For a sense of when Mounjaro typically starts producing noticeable changes, this page on how long Mounjaro takes to work walks through the typical timeline from first injection to meaningful effect.

Step 3: factors that move an individual's result above or below average

Several things pull the real-world figure away from the trial mean, in both directions. Dose reached is the biggest lever: patients who cannot tolerate the higher strengths due to side effects will plateau at a lower average loss. Adherence to a reduced-calorie diet is consistently linked to better outcomes in the trial data; the medicine reduces appetite substantially, but it does not override food choices entirely.

Starting weight also plays a role in percentage terms. Someone starting at 130kg losing 20% reaches a different absolute number than someone starting at 90kg, even if the percentage reduction is similar. Metabolic history, other medicines, activity level, and sleep quality all contribute too, which is why the broader tirzepatide results data shows a range rather than a single fixed outcome.

For a fuller picture of what drives variation in weekly progress specifically, this breakdown of average weekly weight loss on Mounjaro covers the typical range across the titration schedule. If you are weighing Mounjaro against Wegovy, our treatment overview outlines the key clinical differences. And for questions about long-term use, the Mounjaro information page covers the licensed duration and prescriber review process.

One thing to hold onto: average weight loss on Mounjaro in the trials was driven by dual GIP and GLP-1 receptor activation, a different mechanism from earlier medicines. The NHS medicines page for tirzepatide explains how this works in practical terms. If you are ready to find out whether Mounjaro is clinically suitable for you, start your free consultation with our prescribers, reviewed the same day by a GPhC-registered clinician, not a queue for automated software.